Biomarkers of Death Prediction: Are We Currently Going Too Far?

Maria Benito

IPN Communications, Dublin, Ireland

Dr. Maria Benito, IPN Communications, Dublin, Ireland.

Keywords: Biomarkers; Diagnosis; Outcome; Prediction; Respond to Treatment; Death Biomarkers

Abstract

Biomarkers are able to inform about the stage or severity of a particular disorder or differentiate diagnoses. Other biomarkers can predict the evolution and outcome of a disease, or the respond or not to a particular treatment. Currently, there are many biomarkers and they all have a great value as diagnostic and/or prognostic tools.
Some of these examples include rheumatoid factor (RF), erythrocyte sedimentation rate (ESR), C reactive protein (CRP), and the anti-cyclic citrullinated peptide (anti-CCP), used for diagnosis in rheumatoid arthritis (RA); they are associated with the development of a more aggressive disease, extra-articular manifestations and premature mortality in RA patients, and are capable of predicting therapeutic response. Anti-citrullinated peptide antibodies (ACPA) have a predictive role in RA, while antinuclear antibodies (ANA), and have a predictive, prognostic and preventive role [1].

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).